1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55 (2): 74–108.
2. Grandis JR, Melhem MF, Gooding WE et al. Levels of TGF-a and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998; 90 (11): 824–8.
3. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001; 7: 2958–70.
4. Damjanov N, Meropol NJ. Oncology 2004; 479–503.
5. Merck. Data on file, GERBPK001. Merck KGaA.
6. Fan Z, Baselga J, Masui H, Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993; 53: 4637–42.
7. Milas L, Fan Z, Andratschke NH, Ang KK. Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. Int J Radiat Oncol Biol Phys 2004; 58: 966–71.
8. Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000; 6: 2166–74.
9. Iro H, Waldfahrer F. Evaluation of the newly updated TNM classification of head and neck carcinoma with data from 3247 patients. Cancer 1998; 83: 2201–7.
10. Vernham GA, Crowther JA. Head and neck carcinoma-stage at presentation. Clin Otolaryngol Allied Sci 1994; 19: 120–4.
11. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993; 328: 184–94.
12. Decker D, Drelichman A, Jacobs J et al. Adjuvant chemotherapy with high dose bolus cis-diamminodichloroplatinum II (CDDP) and 120 hour infusion 5-fluorouracil (5-FU) in stage III and IV squamous cell carcinoma of the head and neck. ASCO annual meeting 1982, Saint Louis: abstr C-757.
13. Decker D, Drelichman A, Jacobs J et al. Adjuvant chemotherapy with cis-diamminodichloroplatinum II and 120 hour infusion 5-fluorouracil in stage III and IV squamous cell carcinoma of the head and neck. Cancer 1983; 51: 1353–5.
14. Ensley J, Jacobs J, Weaver A et al. Initial cis-platinum combination predicting response to radiotherapy in patients with advanced epidermoid cancers of head and neck. ASCO annual meeting 1982, Saint Louis: abstr C-767.
15. Ensley JF, Jacobs JR, Weaver A et al. Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck. Cancer 1984; 54: 811–4.
16. Bourhis J, Amand C, Pignon J-P, on behalf of the MACH-NC Collaborative Group. Update of MACH-NC (Meta-Analysis of Chemotherapy in Head & Neck Cancer) database focused on concominant chemoradiotherapy. J Clin Oncol ASCO Annual Meeting Proceeding (Post-Meeting Edition) 2004; 22: Abstract 5505.
17. Cohen EE, Lingen MW, Vokes EE. The expanding role of systemic therapy in head and neck cancer. J Clin Oncol 2004; 22: 1743–52.
18. Pivot X, Kataja VV, Jelic S. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of squamous cell carcinoma of the head and neck (SCCHN). Ann Oncol 2005; 16 (Suppl. 1): i62–3.
19. Calais G, Alfonsi M, Bardet E et al. Randomised trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999; 91: 2081–6.
20. Huguenin P, Beer KT, Allal A et al. Concominant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol 2004; 22: 4665–73.
21. Staar S, Rudat V, Stuetzer H et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy-results of multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001; 50: 1161–71.
22. Budach V, Stuschke M, Budach W et al. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. J Clin Oncol 2005; 23: 1125–35.
23. Wendt TG, Grabenbauer GG, Rodel CM et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998; 16: 1318–24.
24. Bernier J, Cooper JS. Chemoradiation after surgery for high-risk head and neck cancer patients: how strong is the evidence? Oncologist 2005, 10 (3): 215–24.
25. Bernier J, Bentzen SM. Altered fractionation and combined radiochemotherapy approaches: pioneering new opportunities in head and neck oncology. Eur J Cancer 2005; 39 (5): 560–71.
26. Nguyen NP, Moltz CC, Frank C et al. Dysphagia following chemoradiation for locally advanced head and neck cancer. Ann Oncol 2004; 15 (3): 383–8.
27. Machtay M, Moughan J, Trotti A et al. Pre-treatment and treatment related risk factors for severe late toxicity after chemo-RT for head and neck cancer: an RTOG analysis. J Clin Oncol 2006; 24 (S18): Abstract 5500.
28. Robert F, Ezekiel MP, Spencer SA et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001; 19 (13): 3234–43.
29. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354 (6): 567–78.
30. Semrau R, Mueller RP, Stuetzer H et al. Efficacy of intensified hyperfractionated and accelerated radiotherapy and concurrent chemotherapy with carboplatin and 5-fluorouracil: Updated results of a randomised multicentic trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2006; [Epub: 4th Feb].
31. Denis F, Garaud P, Bardet E et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004; 22: 69–76.
32. Schantz SP, Harrison LB, Forastiere A. Tumors of the nasal cavity and paranasal sinuses, nasopharynx, oral cavity, and oropharynx. In: Cancer: Principles and Practice of Oncology.
33. DeVita VT, Hellman SA, Rosenberg SA (Eds). Lippincott Williams & Wilkins, PA, USA, 2001; 797–860.
34. Jacobs C et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992; 10: 257–63.
35. Forastiere AA et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992; 10: 1245–51.
36. Clavel M et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1994; 5: 521–6.
37. Gibson MK et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23: 3562–7.
38. Vermorken JB et al. ASCO 2007 (abstract and oral presentation № 6091.
39. Leon X, Hitt R, Constenla M et al. A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Clin Oncol (R Coll Radiol) 2005; 17 (6): 418–24.
40. Baselga J et al. J Clin Oncol 2005; 23: 5568–77.
41. Herbst R et al. J Clin Oncol 2005; 23: 5578–87.
42. Vermorken JB et al. J Clin Oncol 2007; 25: 2171–7.

И.С.Романов, Д.З.Купчан

ГУ Российский онкологический центр им. Н.Н.Блохина РАМН, Москва